Focus of the Report: Substance abuse and drug addiction are conditions that are notoriously difficult to treat with long-term success, as 40% to 60% of patients with drug addiction relapse. Mobile medical applications (MMAs) may fill gaps that currently exist in conventional treatment programs by enabling patients to better manage their care and track their health and wellnes…
PublicationsResearched and Curated by Clinical and Scientific Experts.
Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.
Not all reports are available for public preview. For more information, please contact us.
Revita DMR is an investigational endoscopic hydrothermal ablation device for duodenal mucosal resurfacing proposed for insulin-treated type 2 diabetes.
Tisotumab vedotin is an intravenously administered antibody-drug conjugate targeting tissue factor proposed to treat recurrent or metastatic cervical cancer that has progressed on or following chemotherapy.
The IpsiHand Upper Extremity Rehabilitation System is a brain-computer-interface/robotic arm exoskeleton system for use in chronic stroke patients (≥ 6 months post-stroke) aged ≥ 18 years undergoing stroke rehabilitation, to facilitate muscle re-education and for maintaining or increasing range of motion in the upper extremity.
The OCS Heart is a portable extracorporeal heart perfusion and monitoring system indicated for the resuscitation, preservation, and assessment of donor hearts in a near-physiologic, normothermic, and beating state intended for a potential transplant recipient.
Focus of the Report: This report focuses on the use of peripheral nerve field stimulation (PNFS) to treat refractory chronic low back pain (CLBP).
Technology Description: Peripheral nerve field stimulation is a neuromodulation technology characterized by ease of implant with minimized …
Teplizumab is an intravenously administered anti-CD3 monoclonal antibody in development for the delay or prevention of clinical type 1 diabetes (T1D) in at-risk individuals.
This report evaluates the analytical validity, clinical validity, and clinical utility of the Nodify CDT test.
Breyanzi (lisocabtagene maraleucel [liso-cel]) is an autologous chimeric antigen receptor (CAR) T-cell therapy, a novel type of immunotherapy in which a patient’s own immune cells are genetically re-programmed to target and attack cancer cells. It is indicated for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after 2 or more lines of …